As an innovative clinical stage biotechnology company, we are developing a robust and growing portfolio of novel product candidates generated by Contour®, our proprietary computationally-based SBDD platform. Our team of accomplished scientists utilizes Contour® to rapidly discover highly potent and selective product candidates for validated targets against which the industry has traditionally struggled to develop drugs. We address multiple disease areas including diabetes, Alzheimer’s disease, autoimmune disorders, atopic dermatitis, and acute coronary syndrome.

Patents show all

297Applications158Issued

Clinical Trials show all

2Phase 1/Phase 21Phase 1

SEC Filings show all

8-K3610-Q610-K2D2S-11

SEC Form D Funding Events

DateOfferedSoldType
2009-06-10$15,000,000$15,000,000Equity
2008-09-11UnknownUnknownOther (Paper Filing)

Key Executives

  • Jeffrey Hatfield
    Executive Officer, Director
  • Tina Fiumenero
    Executive Officer
  • Peter Barrett
    Director
  • Robert Gunderson
    Director
  • Donald Hayden
    Director
  • Charles Newhall
    Director
  • Bryan Roberts
    Director
  • James Tananbaum
    Director
  • Richard Gregg
    Executive Officer